Clinical Studies for Improved Therapy

Clinical studies are crucial to understanding the effects of medical cannabis on conditions like chronic pain, epilepsy, and multiple sclerosis. These studies establish a scientific basis that can inform medical decisions and guide therapeutic approaches. A recent study on multiple sclerosis indicates improved quality of life with cannabis therapy, especially in physical and mental health. In palliative care, daily THC doses of 5 mg have shown potential to extend the quality and duration of life in seriously ill cancer patients.

Research also shows promising results in treating endometriosis symptoms. A European study with over 900 participants found that cannabis eased sleep disturbances, pelvic pain, and menstrual cramps. Notably, nearly 90% of patients could reduce traditional pain medication with cannabis, highlighting its potential as an alternative therapy. These clinical studies improve treatment options and help reduce biases within the medical field, promoting cannabis as a credible option in healthcare.

Preclinical Research for New Applications

Parallel to clinical studies, preclinical research is vital for exploring the biological mechanisms and potential new applications of cannabis. Compounds like CBD and THC are studied in laboratory settings to understand their interactions with the human body. This research lays the groundwork for expanding therapeutic uses and refining safety profiles. For example, a study by the University of Bonn showed in mice that low-dose THC administration might slow brain aging processes. An Australian study examined the effects of specific cannabinoids on inflammation and neuroprotective properties, particularly related to neurodegenerative diseases like Alzheimer’s. The findings suggest that cannabinoids can reduce inflammatory markers and prevent nerve cell damage in preclinical models. Such findings provide the foundation for new therapeutic approaches, though clinical trials in humans are needed to confirm these effects.

Studies on Destigmatization and Education As discussed in previous briefings, Switzerland has already launched several scientifically supervised pilot projects examining the impact of regulated cannabis sales on consumption behavior. These findings help differentiate the cannabis discourse and reduce societal prejudices. In Germany, the legal foundation for cannabis regulation has been established with the new Cannabis Act (CanG); only the responsible authority remains to be appointed.

Research in all its forms is key to advancing both medical and societal progress in cannabis. This diversity in research underscores the value of scientific insights for destigmatization, therapeutic application, and social acceptance. Through ongoing studies, cannabis’s potential can be optimally utilized, paving the way for evidence-based regulations.

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

With legalising greetings,

Jakob Sons

Founder & Managing Director Cansativa

Benedikt Sons

Founder & Managing Director Cansativa